Literature DB >> 15446769

Cost of stroke in Sweden: an incidence estimate.

Ola Ghatnekar1, Ulf Persson, Eva-Lotta Glader, Andreas Terént.   

Abstract

OBJECTIVES: To estimate the excess cost of stroke in Sweden and the potential costs that could be avoided by preventing first-ever strokes.
METHODS: We adopted the incidence approach for estimating the present value of both direct and indirect costs. Data on mortality, stroke recurrence, and inpatient care were estimated from a national register of patient data with a four-year follow-up period. To estimate costs for social services, we used survey data on living conditions before stroke onset and at three and at twenty-four months. Costs for outpatient visits, rehabilitation, drugs, and production losses due to premature death and early retirement were estimated on the basis of both published and nonpublished sources. Lifetime costs were based on life tables adjusted for excess mortality of stroke, and costs in year 4 were extrapolated to subsequent years.
RESULTS: The present value direct cost for an average stroke patient is SEK513,800 (USdollars 56,024 or Euro60,825). The corresponding indirect cost is SEK125,110 (USdollars13,640 or Euro14,810). Almost 45 percent of the direct costs were attributable to social services. Women had higher costs than men, and costs for survivors increased with age due to social services.
CONCLUSIONS: With an incidence of 213 first-ever strokes per 100,000 individuals, the total excess direct and indirect cost of stroke would be SEK12.3 billion (approximately US$1.3 billion or Euro1.5 billion). Hence, there are large potential cost offsets both in the health-care sector and in the social service sector if the incidence of first-ever stroke could be reduced.

Entities:  

Mesh:

Year:  2004        PMID: 15446769     DOI: 10.1017/s0266462304001217

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  29 in total

Review 1.  A literature review of indirect costs associated with stroke.

Authors:  Heesoo Joo; Mary G George; Jing Fang; Guijing Wang
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-06-21       Impact factor: 2.136

Review 2.  Cost-effectiveness of statins revisited: lessons learned about the value of innovation.

Authors:  Peter Lindgren; Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2011-04-29

3.  Predictive medicine: towards a multi-parametric imaging for a personal risk stratification.

Authors:  Eric Guedj; Serge Cammilleri; Antoine Verger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02       Impact factor: 9.236

4.  The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation.

Authors:  Thomas Davidson; Magnus Husberg; Magnus Janzon; Lars-Åke Levin
Journal:  J Atr Fibrillation       Date:  2011-02-22

Review 5.  Cost-Effectiveness Of Catheter Ablation Treatment For Patients With Symptomatic Atrial Fibrillation.

Authors:  Nathalie Eckard; Thomas Davidson; Håkan Walfridsson; Lars-Åke Levin
Journal:  J Atr Fibrillation       Date:  2009-08-01

6.  The cost of pediatric stroke acute care in the United States.

Authors:  Elizabeth Perkins; Julie Stephens; Huiyun Xiang; Warren Lo
Journal:  Stroke       Date:  2009-07-09       Impact factor: 7.914

7.  Economic burden of stroke: a systematic review on post-stroke care.

Authors:  S Rajsic; H Gothe; H H Borba; G Sroczynski; J Vujicic; T Toell; Uwe Siebert
Journal:  Eur J Health Econ       Date:  2018-06-16

8.  [Long-term disease-related costs 4 years after stroke or TIA in Germany].

Authors:  Y Winter; C Wolfram; O Schöffski; R C Dodel; T Back
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

9.  Economic burden of stroke.

Authors:  Afitap İçağasıoğlu; Hatice Şule Baklacıoğlu; Erkan Mesci; Yasemin Yumuşakhuylu; Sadiye Murat; Nilgün Mesci
Journal:  Turk J Phys Med Rehabil       Date:  2017-06-03

10.  Impact of Intensive Gait Training With and Without Electromechanical Assistance in the Chronic Phase After Stroke-A Multi-Arm Randomized Controlled Trial With a 6 and 12 Months Follow Up.

Authors:  Susanne Palmcrantz; Anneli Wall; Katarina Skough Vreede; Påvel Lindberg; Anna Danielsson; Katharina S Sunnerhagen; Charlotte K Häger; Jörgen Borg
Journal:  Front Neurosci       Date:  2021-04-22       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.